New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For PCL;LH;DNB;SNTA;ESI;FLIR From The Last 14 Days
Check below for free stories on PCL;LH;DNB;SNTA;ESI;FLIR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
11:23 EDTLHQuest Diagnostics shares recommended at Maxim
Subscribe for More Information
April 17, 2014
09:59 EDTPCLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AcelRx (ACRX) initiated with a Buy at Canaccord... Acorda Therapeutics (ACOR) initiated with a Hold at Canaccord... Alcobra (ADHD) initiated with a Buy at Canaccord... Benefitfocus (BNFT) initiated with a Market Perform at William Blair... Cameron (CAM) initiated with a Buy at Gabelli... Covanta (CVA) initiated with an Outperform at Macquarie... Foundation Medicine (FMI) initiated with a Market Perform at William Blair... Golub Capital (GBDC) initiated with an Outperform at Raymond James... Hanmi Financial (HAFC) initiated with an Outperform at Raymond James... Jazz Pharmaceuticals (JAZZ) initiated with a Buy at Canaccord... Kronos Worldwide (KRO) initiated with a Reduce at SunTrust... Magnum Hunter (MHR) initiated with a Hold at Maxim... Norwegian Cruise Line (NCLH) initiated with a Buy at Longbow... Plum Creek Timber (PCL) initiated with an Outperform at RBC Capital... RF Micro Devices (RFMD) initiated with a Market Perform at BMO Capital... SanDisk (SNDK) assumed with an Overweight at Piper Jaffray... Skyworks (SWKS) initiated with a Market Perform at BMO Capital... TransEnterix (TRXC) initiated with a Buy at Sterne Agee... TriQuint (TQNT) initiated with a Market Perform at BMO Capital... WebMD (WBMD) initiated with an Outperform at William Blair.
08:32 EDTLHARCA Biopharma announces screening of first patient in Phase 2B/3 trial
ARCA biopharma announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro as a potential treatment for the prevention of atrial fibrillation in patients with heart failure and/or left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor, which is believed to be present in approximately 50% of the U.S. population. There are currently seven active clinical trial sites recruiting patients for GENETIC-AF. The company anticipates having approximately 50 clinical trial sites for the Phase 2B portion of the trial. Last week, ARCA hosted the initial GENETIC-AF Investigator Meeting which brought together the physicians and research coordinators participating in the trial for information sharing and study-specific training.
07:33 EDTDNBD&B acquires Fliptop's social data matching business unit
Subscribe for More Information
April 16, 2014
17:11 EDTPCLPlum Creek Timber initiated with an Outperform at RBC Capital
Subscribe for More Information
April 15, 2014
07:33 EDTFLIRFLIR Systems receives full-rate production decision for CBRNE system
Subscribe for More Information
April 14, 2014
16:54 EDTESIPoint72 raises passive stake in ITT Educational to 5.7% from 5.0%
Subscribe for More Information
08:02 EDTSNTASynta sells $5M in common stock directly to affiliate of board member
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use